Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 16/20 | 0.39 |
| ▸ | HTR2A | P28223 | 15/20 | 0.39 |
| ▸ | DRD3 | P35462 | 15/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6077269 | 0.83 | MGAM (0.55) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL6076290 | 0.83 | DRD2 (0.45) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL6679348 | 0.77 | HTR2C (0.51) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL6679351 | 0.77 | HTR2C (0.51) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL6676704 | 0.76 | MTNR1A (0.57) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL6676706 | 0.76 | MTNR1A (0.57) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL8485225 | 0.75 | ABCG2 (0.40) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL6678551 | 0.74 | MTNR1B (0.67) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL6678547 | 0.74 | MTNR1B (0.67) | MGAMAMY1AGAASIMGAM2 | |
| SCHEMBL8488787 | 0.74 | MGAM (0.46) | MGAMAMY1AGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112584-B2 | Nonsteroidal antiinflammatory agents | SCHERING AG (DE) | 2006-09-26 | — | — | US | disclosed |
| EP-1572671-A1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2005-09-14 | — | — | EP | disclosed |
| US-20040209875-A1 | Nonsteroidal antiinflammatory agents | SCHERIN AKTIENGESELLSCHAFT (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004058733-A1 | NON-STEROIDAL ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209875-A1 | Nonsteroidal antiinflammatory agents | PTGS1, PTGER1, PTGES | MGAM 2064/4885AMY1A 234/4885GAA 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.